An accumulation of negative life events and the construction of alexithymia: a longitudinal and clinical approach.

J Pers Assess

Groupe de Recherches en Psychologie clinique et pathologique de la Sante-Laboratoire de Psychologie de l'interaction et des relations intersubjectives, University Nancy 2, Nancy cedex, Lorraine, France.

Published: May 2010

We began the study with a theoretical comparison of the concepts of alexithymia and operative thought in terms of etiology as well as with a specific approach to comparing the concepts using the Rorschach Inkblot Method (Rorschach, 1921) with both Exner's (1986) Comprehensive System and the Parisian School (Chabert, 1983, 1987; Rausch de Traubenburg, 2000) methods of coding and interpretation. We then present a longitudinal clinical study of a woman suffering perinatal depression starting at 8 months gestation until 34 months postpartum. The case shows how an accumulation of stressful and traumatic life events in the early perinatal period generates a reactive, structured alexithymia. This psychic process transforms an initial acceptance of therapy into a refusal to engage in a therapeutic alliance along with persistent depressive symptoms, impaired quality of life, and maladaptive coping strategies.

Download full-text PDF

Source
http://dx.doi.org/10.1080/00223891003670125DOI Listing

Publication Analysis

Top Keywords

life events
8
longitudinal clinical
8
accumulation negative
4
negative life
4
events construction
4
construction alexithymia
4
alexithymia longitudinal
4
clinical approach
4
approach began
4
began study
4

Similar Publications

Approaches for difficult-to-induce-seizures electroconvulsive therapy cases (DEC): a Japanese expert consensus.

Ann Gen Psychiatry

January 2025

Department of Neuropsychiatry, Faculty of Life Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-Ku, Kumamoto, 860-8556, Japan.

Background: Seizure threshold increases with age and the frequency of electroconvulsive therapy (ECT). Therefore, therapeutic seizures can be difficult to induce, even at maximum stimulus charge with available ECT devices. Such cases are known as difficult-to-induce-seizures electroconvulsive therapy cases (DECs).

View Article and Find Full Text PDF

The Efficacy and Safety of Angiotensin II for Treatment of Vasoplegia in Critically Ill Patients: A Systematic Review.

J Cardiothorac Vasc Anesth

December 2024

Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy; School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. Electronic address:

Objectives: To summarize evidence regarding intravenous angiotensin II administration in critical illness and provide an updated understanding of its effects on various organ dysfunction and renin-angiotensin system (RAS) biomarkers.

Design: A systematic review.

Setting: A search of PubMed, Embase, and the Cochrane Library from inception to May 3, 2024.

View Article and Find Full Text PDF

Amidine-functionalized aggregation-induced emission luminogen and a 3D-printed digital sensor platform for ultrafast and visual detection of heparin.

Anal Chim Acta

February 2025

College of Chemistry, Henan Joint International Research Laboratory of Green Construction of Functional Molecules and Their Bioanalytical Applications, Food Laboratory of Zhongyuan, Zhengzhou University, Zhengzhou, 450001, China.

Background: Heparin is a widely used anticoagulant in clinic. However, improper dosing can increase the risk of thromboembolic events, potentially leading to life-threatening complications. Clinic monitoring of heparin is very important for its use safety.

View Article and Find Full Text PDF

Background: There are no approved oral disease-modifying treatments for Alzheimer's disease (AD).

Objectives: The objective of this study was to assess efficacy and safety of blarcamesine (ANAVEX®2-73), an orally available small-molecule activator of the sigma-1 receptor (SIGMAR1) in early AD through restoration of cellular homeostasis including autophagy enhancement.

Design: ANAVEX2-73-AD-004 was a randomized, double-blind, placebo-controlled, 48-week Phase IIb/III trial.

View Article and Find Full Text PDF

Background: SL-172154 is a hexameric fusion protein adjoining the extracellular domain of SIRPα to the extracellular domain of CD40L via an inert IgG-derived Fc domain. In preclinical studies, a murine equivalent SIRPα-Fc-CD40L fusion protein provided superior antitumor immunity in comparison to CD47- and CD40-targeted antibodies. A first-in-human phase I trial of SL-172154 was conducted in patients with platinum-resistant ovarian cancer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!